Seth Harrison, founder and managing partner of ATP, has been investing in life sciences since 1991. Prior to starting ATP in 1999, Seth was a general partner at Oak Investment Partners, and before that a venture partner at Sevin Rosen Funds. Some of his earlier investments include Aileron Therapeutics, ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, HeartWare International, Informed Access, SGX Pharmaceuticals, Syntimmune, Tendyne, Ultracision, and ViroPharma. From 2002 to 2010, he also served on the board of the International Partnership for Microbicides.
Seth received an AB from Princeton University, an MD and MBA both from Columbia University, and completed a surgery internship at the Presbyterian Hospital in the City of New York.
Marie-Therese Afif is head of operations for ATP. She brings to the role more than 30 years of experience supporting private investment funds with expertise in operations, administration, and human resources, as well as legal and compliance matters. Marie-Therese has worked with ATP for more than 13 years, including at the firm’s inception in 1999. She also worked with the privately owned hedge fund H/2 Capital Partners for nearly a decade.
Marie-Therese earned her undergraduate degree from Kantonsschule Heerbrugg, Lehrerseminar, Switzerland, and she obtained a certificate in financial analysis from New York University.
Anna Batarina, a partner at ATP, is a leader in international business, capital markets, corporate finance, and strategy. For more than a decade, Anna held positions of increasing responsibility at Uralkali, a leading global agrochemical business, culminating as senior vice president, head of Capital Markets and Investor Relations. At Uralkali, she implemented best-in-class corporate governance processes, executed a series of industry consolidation transactions, and led one of the most successful IPOs on the London Stock Exchange. Prior to Uralkali, Anna was an Associate at A1/Alfa Eco, Russia’s largest private equity firm, and before that was a senior consultant in Financial and International Tax Services for Ernst & Young. More recently, she was a member of the strategy team at the Global Fund to Fight AIDS, Tuberculosis and Malaria.
Anna received an MA in Global Affairs (Global Health track) and a graduate certificate in Global Health, Public Health from Yale University. She holds an MS in clinical psychology from Lomonosov Moscow State University, a BS in finance from Financial University under the Government of the Russian Federation, and a CFA charter.
Andrew Bayliffe is a venture partner at ATP. With more than 20 years of leadership experience in the biopharmaceutical industry, he possesses expertise in the discovery and development of both small molecule and antibody therapeutics across a broad range of diseases areas. Most recently, at GlaxoSmithKline (GSK), he served as head of the Fibrosis and Lung Injury Discovery unit at GSK’s R&D headquarters in Stevenage, UK, and held senior roles in antibody discovery and development in the US and UK.
Andrew is an honorary professor at the Wolfson Institute of Experimental Medicine at Queens College in Belfast. He completed his undergraduate and PhD studies in pharmacology, physiology, and molecular biology at Manchester University and Leeds University in the UK.
Raj Chopra is a venture partner at ATP. At The Institute of Cancer Research in London, as director of the Cancer Research UK Cancer Therapeutics Unit, he led one of the largest academic drug discovery groups in the world and focused on targeted protein degradation and complex 3D cell culture models. Raj also worked at Celgene from 2009 to 2016 as corporate vice president of Translational and Early Drug Development, leading an international team of more than 100 scientists. Before joining Celgene, he held leadership positions in AstraZeneca’s Oncology Therapeutics group in the UK and US. Raj started his academic career as the director of Hematological Oncology at Christie Hospital and was group leader at the Paterson Institute of Cancer Research, both located in Manchester, UK. He is a non-executive director of Artios Pharma, established to develop a next-generation DNA damage response target pipeline of cancer therapeutics, and co-founder of Monté Rosa Therapeutics, a biotech focused on targeted protein degradation.
Raj trained in medicine at University College London, where he earned his PhD in medicine, cell and molecular biology. He is a fellow of the Royal College of Physicians of London, the Royal College of Pathologists, and the Royal Society of Biology.
Michael Ehlers is chief scientific officer and a venture partner at ATP, applying expertise gained through a successful career leading research and development at major biopharmaceutical companies. Most recently, Mike was executive vice president for Research and Development at Biogen, where he led discovery sciences, translational medicine, clinical development, and regulatory sciences, with a focus on neurological, immunological, and rare diseases. He significantly expanded and diversified Biogen’s clinical portfolio, transformed its R&D productivity, advanced more than 20 novel clinical candidates, and oversaw global filings and approvals of Spinraza™️ (nusinersin), the first drug approved for spinal muscular atrophy. Prior to Biogen, Mike was Biotherapeutics group senior vice president and Neuroscience chief scientific officer at Pfizer, where he created and advanced the neuroscience and rare disease portfolios; directed global development activities in biologics design, synthesis, and manufacturing; steered academic collaborations focused on immunology and oncology; and successfully brought 22 compounds into the clinic. Before entering industry in 2010, Mike was a professor and investigator at the Howard Hughes Medical Institute at Duke University Medical Center, where he pioneered studies on neuronal organelles and the trafficking of neurotransmitter receptors. He has received numerous awards, authored more than 100 scientific papers, and served on multiple editorial boards as well as advisory boards for the National Institutes of Health, private foundations and many other organizations spanning industry, academia and government.
Mike earned a BS in chemistry from the California Institute of Technology and holds MD and PhD degrees from the Johns Hopkins University School of Medicine.
Paul Eisenberg, chief medical officer and venture partner at ATP, brings more than 30 years of experience in drug development across therapeutic areas. At Eli Lilly, Paul held leadership roles in Cardiovascular Discovery and Translational Medicine, later stage drug development and commercialization, and drug safety. He subsequently joined Amgen, where he led Global Regulatory and Safety and was involved in the development and global registration of all Amgen products from 2006 through 2014. Subsequently, Paul led Amgen’s Global Medical Affairs organization, focusing on the challenges of access to innovative therapies and representing Amgen in PDUFA V negotiations. His academic basic and clinical research focused on mechanisms of thrombosis in ischemic heart disease and in response to fibrinolytic therapy, and his research contributed to the development of novel anti-thrombotic therapies. He has 80 peer-reviewed publications of original research, as well as more than 40 contributions to reviews and books.
Paul received his MD from New York Medical College and MPH in Tropical Medicine from the Tulane University School of Public Health and Tropical Medicine. After completing training in internal medicine, cardiology and pulmonary diseases at Washington University, he joined the faculty of the Department of Medicine ultimately as Professor of Medicine and was the Director of the Cardiac Intensive Care Unit at Barnes-Jewish Hospitals.
Jim Faulkner is a venture partner at ATP. A highly experienced biopharmaceutical development leader with specialist skills in gene and cell therapy, he has been significantly involved in taking more than 25 different medicines into the clinic, including multiple CAR-T assets. Most recently, Jim headed Product Delivery for Autolus Ltd, a clinical-stage CAR-T company spun out of University College London. During his tenure, he set up and led a team of over 75 scientists and engineers in the US and UK responsible for process development, technical operations, engineering and supply chain, and he served on the leadership team that took Autolus from start-up to successful IPO in three years. Prior to that, Jim held various leadership roles at GlaxoSmithKline, including overseeing the chemistry, manufacturing and controls (CMC) development and supply of a portfolio of pioneering product types that included gene and cell therapies, oligonucleotides, therapeutic enzymes, and molecular chaperones, and playing a significant role in the successful filing of the first-ever autologous ex vivo gene/cell therapy product license (for Strimvelis™). He started his career at British Biotech, the first biotechnology company to be publicly listed in the UK.
Jim earned a BSc in biotechnology from the University of Leeds and completed his PhD in molecular biology at the Centre for Applied Microbiology and Research.
Daniel Finkelman, general counsel for ATP, has more than 45 years of experience as a corporate and partnership attorney specializing in the representation of private investment funds and has represented funds in raising more than $50 billion of committed capital.
Dan has served as ATP’s principal funds counsel for 20 years and joined the firm after retiring as a partner at Proskauer Rose. He earned his JD and MBA from Columbia University.
Sally Jacob is head of communications for ATP. Her experience in biopharmaceutical industry corporate affairs and life sciences communications spans more than two decades. As vice president, Communications, for Pfizer’s Medical and Global Product Development divisions, she collaborated with company leaders and outside partners to create and operate initiatives in research transparency, compassionate use, clinical trials awareness, and public health education. She led communications for the Series A raise and launch of SpringWorks Therapeutics, a spinout created to develop and commercialize several Pfizer pipeline programs in rare diseases. Prior to joining Pfizer, Sally led corporate brand communications for Amgen, and before that she held various positions in Corporate Affairs at Bristol-Myers Squibb.
Sally earned an AB in history from Princeton University and an MA in English from Cornell University.
Spiros Liras is a venture partner at ATP, building on a career leading scientific innovation and discovery at some of the world’s leading pharmaceutical companies. Most recently, Spiros was with Biogen, where he established and led the External Portfolio Innovation unit within Research and Development. Prior to his employment at Biogen, Spiros was vice president of Medicinal Chemistry at Pfizer, where he led teams to deliver clinical pipelines in disease areas including cardiovascular and metabolic diseases and neuroscience. Under his leadership, his divisions explored cutting edge drug discovery concepts including selective protein translation inhibition, design of macrocycles for drug discovery in tough target space, allosterism, and tissue targeting design strategies for the delivery of small molecule, oligonucleotide therapeutics and other modalities.
Spiros earned a PhD in organic chemistry from Iowa State University in 1990 and completed postdoctoral studies at the University of Texas at Austin. He currently serves as adjunct full professor in the department of Pharmaceutical Chemistry at the University of California, San Francisco.
Stephanie Maiocco, a scientist-in-residence at ATP, is focused on innovative protein engineering. She has designed, optimized, and executed laboratory experiments using a wide array of innovative in vitro methodologies and provided novel solutions to protein design and assay development. Prior to joining ATP, Stephanie contributed to innovative protein technology platforms at both Akrevia Therapeutics and Elstar Therapeutics. She is a co-inventor on multiple patents for bi-specific antibodies and protein therapeutics.
Stephanie earned a BS in chemistry from Gettysburg College and a PhD in chemistry from Boston University, where her thesis was focused on the biochemical and biophysical characterization of redox-active enzymes containing multiple metallocofactors from both the radical S-adenosylmethionine and cytochrome c peroxidase enzyme superfamilies.
Raj Mehta, an entrepreneur-in-residence at ATP, is a serial entrepreneur with experience identifying, nurturing, fundraising, and launching multiple immunology- and oncology-focused spinoffs, and a business development professional with a 20-year track record of building lasting partnerships. At GammaDelta Therapeutics, he served as co-founder, interim CEO, board member and director of business development. At GammaDelta, Raj led a $100-million fundraising effort, established an innovative partnership with Takeda Pharmaceuticals, managed the acquisition of Lymphact, and spearheaded the spinoff of Adaptate Biotherapeutics. Prior to GammaDelta, Raj spent nearly 18 years at Cancer Research Technology (CRT), where he held a variety of leadership roles. At CRT, Raj served as co-founder, interim CEO, and board member of BliNK Therapeutics and Revitope Oncology, established Fastbase Solutions, and led more than 25 licensing and collaborative partnerships. He joined CRT from MRC Collaborative Centre, where he led the Merck KGaA Group.
Raj earned a natural sciences degree from University of Cambridge and completed his doctoral research at the National Institute for Medical Research, now part of Francis Crick Institute, in London.
Phil Patten is an entrepreneur-in-residence at ATP, building on a career leading scientific innovation and discovery. Phil was a founder and chief scientific officer of DiCE Molecules, a biotechnology company focused on the use of DNA-encoded libraries to discover and optimize oral inhibitors of challenging protein-protein interface targets. An oral inhibitor of IL-17A discovered at DiCE is in advanced preclinical testing. Before joining DiCE, Phil was at Pioneer Hi-Bred, where he was a DuPont Fellow and managed teams that utilized directed evolution and synthetic biology in agriculture. Prior to that, he was senior vice president of Biology at Achaogen, where he led a team that discovered and brought forward the first clinical stage small molecule inhibitor of LpxC. Phil started his industrial career at Maxygen, where he applied directed evolution to therapeutic proteins and led a team that discovered an evolved type I interferon that was advanced to clinical studies in collaboration with Roche. He is an inventor on more than 90 granted US patents and has served on multiple scientific advisory boards. He currently serves on the Biology and Bioengineering Chair’s Council at the California Institute of Technology.
Phil earned a BS in biology from the California Institute of Technology and a PhD in biological sciences from Stanford University, and completed postdoctoral studies in chemistry at the University of California, Berkeley.
John F. Reilly is an entrepreneur-in-residence at ATP, building on over 20 years of biopharmaceutical leadership and drug discovery experience across multiple disease areas. John was senior vice president of Biology at Goldfinch Bio, where he led efforts ranging from target discovery to clinical biomarkers. Prior to joining Goldfinch, John served as executive director of Biology at Catabasis Pharmaceuticals, where he was responsible for developing and executing a translational strategy for several molecules with potential applications in multiple rare diseases. Previously he was global head of Applied Human Genetics & Genomics at Novartis Institutes for BioMedical Research, where he led a multi-disciplinary department driving advancements in genomic technologies and their application to clinical trials across general medicine indications. At Merck Research Laboratories, he served as director of Molecular Biomarkers, leading the company’s anti-PD-1 biomarker efforts and developing and qualifying biomarker assays for use in discovery and early-stage clinical trials in multiple programs. John earned a BA in molecular and cell biology from the University of California Berkeley, a PhD in neuroscience from the University of California Davis, and completed postdoctoral training at the Scripps Research Institute.
Victor Rusu, an associate at ATP, is focused on emerging targets and technologies, with specific experience and expertise in cell biology and functional genomics. Victor was a member of the biotech equity research team at Citigroup, and before that, he was one of the first scientists at Jnana Therapeutics, a biotechnology company focused on building a drug discovery platform to systematically target SLC transporters.
Victor earned a PhD from Harvard University and completed his graduate school training at the Broad Institute. During his time at Harvard, Victor identified distinct molecular mechanisms through which coding and noncoding mutations in an uncharacterized transporter increase type 2 diabetes risk.
Namrata Turaga, an associate with ATP, brings a mix of professional and medical experience to her role. At Boston Consulting Group, she worked as a management consultant across the pharmaceutical, private equity, and consumer industries. Her venture capital experience includes work with Flagship Ventures and Oxford Sciences Innovation. She gained broad expertise across the healthcare industry through previous collaborations with Genentech, DaVita, and the International Consortium for Health Outcomes Measurement. She is a member of the Royal College of General Practitioners and is a practicing physician.
Namrata earned an MA in medical sciences with a focus on neuroscience, as well as her medical degree, from St John’s College at Oxford University. She then pursued her MBA at Harvard Business School as a Fulbright Scholar before completing her medical training and residency in the Oxford Deanery.
Brian Vash is an entrepreneur-in-residence at ATP focusing on innovative protein engineering. Brian has more than 20 years of hands-on experience designing and producing novel proteins, including 18 years in the pharmaceutical industry contributing to drug discovery pipelines and intellectual property. Before joining ATP, Brian was an early member of the leadership team at Elstar Therapeutics, where as director of protein engineering and technology development, he was responsible for establishing the company’s protein engineering and biologics production functions. Brian played a critical role in the development of Elstar’s novel kappa/lambda bispecific antibody platform, along with other innovative protein designs. Prior to that he spent 12 years at Novartis as a scientist working on structural biology and biologics, contributing to both the small molecule and protein therapeutics pipelines. While at Novartis, Brian was an inventor on patents covering alternative scaffolds, therapeutic proteins, and CAR-T therapy.
Brian earned a BS in biochemistry from the University of Texas at Arlington.
Jonathan Waldstreicher, a partner at ATP, has worked in medical devices as an entrepreneur, investor, and clinician. Jon founded Gala Therapeutics in 2015 and serves as the company's CEO. Prior to joining ATP, Jon was a director, Global Surgery R&D, at Johnson & Johnson. He started at Johnson & Johnson as an associate director in the Corporate Office of Science & Technology. Before medical school, Jon worked in Equity Research at Bear Stearns.
Jon received a BA from Brandeis University in economics and an MD and MBA from Tufts University School of Medicine. He completed a general surgery internship at Tufts Medical Center in Boston.
Joseph Yanchik, a venture partner at ATP, has been founding and funding life science companies for more than 20 years. In 2005, Joe founded ATP portfolio company Tokai Pharmaceuticals, focused on biopharmaceutical treatments for prostate cancer, serving as president and CEO from 2005 to 2008 and then as a director through 2017. Concurrently, Joe founded ATP portfolio company Aileron Therapeutics, focused on developing a novel class of stabilized cell-permeating peptides called stapled peptides, for cancer and other diseases. He established a $1.1 billion partnership between Aileron Therapeutics and Roche Pharmaceuticals and led Aileron from inception to public listing, serving as president, CEO, and director from 2006 to 2018. Previously, Joe served as vice president of corporate development at Mendel Biotechnology, an agricultural biotech company, and founded and served as chief financial officer of Poetic Genetics, a gene therapy company. He began his career practicing corporate and securities law at Cahill Gordon & Reindel, where he specialized in public securities offerings, high-yield debt financings, and M&A. He then moved to Venture Law Group in Menlo Park, where he specialized in financing early-stage life science and technology companies.
Joe received a bachelor's degree from Loyola College in Maryland and a JD from the Villanova University School of Law, where he was managing editor of the Law Review. He is a member of the New York, California, and District of Columbia bars.